HC Wainwright Raises Context Therapeutics (NASDAQ:CNTX) Price Target to $5.00

Context Therapeutics (NASDAQ:CNTX) had its price objective increased by HC Wainwright from $4.00 to $5.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 173.22% from the stock’s previous close.

Separately, Maxim Group upped their price objective on Context Therapeutics from $4.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday.

Context Therapeutics Stock Performance

Shares of NASDAQ:CNTX traded up $0.02 during mid-day trading on Thursday, hitting $1.83. 598,465 shares of the company traded hands, compared to its average volume of 375,512. The firm’s 50 day simple moving average is $1.33 and its 200 day simple moving average is $1.15. Context Therapeutics has a 52-week low of $0.47 and a 52-week high of $2.01.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Thursday, March 21st. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.07). On average, sell-side analysts forecast that Context Therapeutics will post -1.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

A hedge fund recently bought a new stake in Context Therapeutics stock. Opaleye Management Inc. purchased a new stake in shares of Context Therapeutics Inc. (NASDAQ:CNTX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 975,000 shares of the company’s stock, valued at approximately $1,102,000. Opaleye Management Inc. owned approximately 6.11% of Context Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.